Document is current
Any future updates will be listed below
-
Authors
Garmezy, Benjamin https://orcid.org/0000-0003-2790-6235
Grossman, Joseph E.
Buell, Jennifer https://orcid.org/0000-0001-7405-0076
Favano, Thiago https://orcid.org/0000-0002-3927-2025
Stebbing, Justin https://orcid.org/0000-0002-1117-6947
O’Day, Steven
Purbhoo, Marco A. https://orcid.org/0009-0001-5541-5233
Chand, Dhan
Greco, F. Anthony
- License Information
-
More Information
Article History
Received: 17 March 2025
Revised: 8 May 2025
Accepted: 24 June 2025
First Online: 10 July 2025
Competing interests
: BG reports research funding and/or consulting (all paid to his institution) for Abbvie, Accutar Biotechnology, Arcus Biosciences, Arvinas, AstraZeneca, AVEO Oncology, CRISPIR Therapeutics, Eikon Therapeutics, Exelixis, Roche/Genetech, Flare Therapeutics, Harbor BioMed, IDEAYA Biosciences, Janssen, Janux Therapeutics, Jubilant Therapeutics, Kineta, Kinnate BioPharma, Loxo, Mink Therapeutics, Nuvation Bio, Profound Bio, Takeda Therapeutics, Teon Therapeutics, Tmunity Therapeutics, Xencor, Zenshine, Adaptimune, Adicet Therapeutics, AIQ Global, Amgen, Arcus Biosciences, Bayer, Bicycle Therapeutics, Easai, EMD Serono, Merck, Novartis, Pfizer, Rondo Therapeutics, Sanofi-Aventis, Seagen, Xencor. FAG reports payments from Hologic/BioTheranostics, for JS from 2022 to present JS has been Editor-in-Chief of Oncogene (no role in the review process here) and has sat on SABs/advisory boards for Lilly, Agenus, Celltrion, Enhanced, Glyphic, Greenmantle, vTv Therapeutics, APIM, Onconox, IO Labs, Clinical Ink, Zephyr AI, Benevolent AI, Biozen, Pear Bio, Sable Bio and Linkgevity. He has consulted with Lansdowne partners and Vitruvian. Since 2024 he has been a board member for Graviton Bioscience BV, Etira Therapeutics and Portage, and previously chaired the board of BB Biotech Healthcare Trust PLC. All other authors report employment, shares and salaries at MiNK Therapeutics or Agenus Inc.
